PepGen Inc. (PEPG)
2.32
-0.13
(-5.31%)
USD |
NASDAQ |
Nov 05, 16:00
2.29
-0.03
(-1.29%)
After-Hours: 20:00
PepGen SG&A Expense (TTM) : 23.44M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 23.44M |
| March 31, 2026 | 22.56M |
| December 31, 2025 | 22.57M |
| September 30, 2025 | 22.10M |
| June 30, 2025 | 22.32M |
| March 31, 2025 | 22.14M |
| December 31, 2024 | 21.26M |
| September 30, 2024 | 20.39M |
| June 30, 2024 | 19.18M |
| March 31, 2024 | 18.04M |
| December 31, 2023 | 16.64M |
| September 30, 2023 | 16.18M |
| Date | Value |
|---|---|
| June 30, 2023 | 15.53M |
| March 31, 2023 | 14.71M |
| December 31, 2022 | 14.22M |
| September 30, 2022 | 12.85M |
| June 30, 2022 | 11.62M |
| March 31, 2022 | 8.222M |
| December 31, 2021 | 5.372M |
| September 30, 2021 | 2.894M |
| March 31, 2021 | 0.528M |
| December 31, 2020 | 0.528M |
| September 30, 2020 | 0.192M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Korsana Biosciences, Inc. | 7.127M |
| IRulya Therapeutics, Inc. | 27.81M |
| Q32 Bio, Inc. | 13.91M |
| Bridgebio Oncology Therapeutics, Inc. | 36.80M |
| Arrowhead Pharmaceuticals, Inc. | 172.57M |